Oramed Pharmaceuticals Inc. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4/A — Form 4/A

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-08-31

Reporting Person: KIDRON NADAV (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-31	Common Stock	A	100000	—	Acquired	838209	Direct

Footnotes

F1: Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis.

F2: This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 748,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 838,209 shares of common stock following the reported transaction.